Harrow vs Rigel Pharmaceuticals
Harrow and Rigel Pharmaceuticals are similar in size: $272m and $294m of revenue in their latest fiscal years. Rigel Pharmaceuticals grew faster (64.1% against 36.4%). Rigel Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 124.7% against -1.9%.
| Latest fiscal year | HarrowHROW, 2025 | Rigel PharmaceuticalsRIGL, 2025 |
|---|---|---|
| Revenue | $272m | $294m |
| Revenue growth | 36.4% | 64.1% |
| Net income | −$5.1m | $367m |
| Operating margin | — | 42.6% |
| Net margin | -1.9% | 124.7% |
| Return on equity | -8.4% | 185.9% |
| Free cash flow | $43.0m | $75.7m |
| Cash | $72.9m | $40.6m |
| Total debt | $250m | $52.5m |
| Debt to equity | — | 13.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $1.06bn | $889m |
| Price vs our value range | Above our value range | Below our value range |
| Moat score | 26 (Weak) | 29 (Weak) |
| Insider trades, 12 months | 4 buys, 7 sales | 0 buys, 3 sales |